We would love to hear your thoughts about our site and services, please take our survey here.
Algo is hoovering up shares today. I always find it strange how an algo seems to be keenly programmed specifically for this stock. Surely that’s abnormal for a nano-cap like ETX? The price is so sensitive to any volume that it must be borderline manipulative (I’m not suggesting that’s what’s happening).
I hope you’re right. Any good company stock will drift on low volume and news flow, especially minnows, so it’s not unexpected; just unfortunate and frustrating.
Above the mid price so a good signal (hopefully). Would be nice if ETX had a catalyst to end this downward drift. Too quiet recently.
Rns just out - Yesterday Quested increased his position to 11.76%. Same names here that were involved with Silence Therapeutics, which inspires confidence. Let’s hope they deliver.
I quoted 8 Feb sometime within the last couple of weeks as it’s what Yahoo Finance stated. It appears I was wrong as Eton are still silent. Looking more like a March earnings release. Personally I’m not expecting fireworks as it’s early days, and I wonder if Eton’s ability to distribute Alkindi was affected by Covid, like it was for Diurnal.
Excuse the repeat of “well placed”. I hate doing that...
iseenoships thanks for the link. It’s a very interesting interview and ETX seem very well placed. The vibe I get is that they’re very well placed, albeit a little ahead of the curve and computational power improvements are really the primary bottleneck for their platform. In silico drug design is what enabled the covid vaccines to be developed so quickly, and within the UK, ETX seems like a great stock to get exposure to this undoubtedly lucrative sector. They likely need a few more years though. One to be patient with.
Attack of the algos today. Let’s hope the momentum continues. ETX is arguably a more obscure, under the radar pick, but with such a concentrated group of shareholders, all of whom have had a lot of success in other biotechs (Silence Theraputics springs to mind), I’m confident. My main concern is financing. How long will the proceeds from the most recent placing last?
I don’t think I’ve seen an aim stock move so little on a continuous string of good news. Perhaps the chronocort “failure” a while back has knocked confidence ever since. I must say that approval seems almost a given now, although there’s always a chance for a surprise. If DNL doesn’t play out then I’ll probably just quit the markets for good, because I can’t see another obvious opportunity like this one.
I’m keen to hear what Eton have been up to. For anyone unaware, their earnings call is Monday 8th Feb. They seemed excited about Alkindi interest, but if DNL figures are anything to go by then perhaps we need covid to subside before take up really gains traction.
I’ve considered selling my position recently, but I just can’t do it. The fundamentals look good, and although the false dawns are frustrating, we just need to be patient. Perhaps the price is dropping to attract sellers as it’s quite illiquid, and anyone looking to buy in size simply won’t be able to. With that, you’d expect the price to move UP if there were buyers lining up, but alas, this is aim...
It’s quite a puzzling valuation, when there are other pharmas with absolutely no revenue stream (let alone a growing one) and nothing but hype driving the prices to wild highs.
My thoughts however are that DNL is now too predictable. We know the pipeline products and their market size, and the somewhat underwhelming sales report for Alkindi is taking a **** on what should be Chronocort approval fireworks. Very little seems left to the imagination at this point, and thus there is no excitement.
I look forward to Eton’s sales figures. Perhaps the US and Canadian markets are the key for Alkindi (and thus Chronocort) sales. At this point however, they cannot afford to be anything other than spectacular.
Given time, the fair value of DNL will out, but I’m beginning to wonder what other opportunities I’ll miss out on in the meantime, should I sit patiently.
A decent £120k buy at the end of the day to restore a little confidence.
It seems we’re mostly aligned on sentiment here, which is refreshing, as the boards on this site are so toxic sometimes I don’t even bother posting.
Right now markets globally are chasing only the highest, most ludicrous growth rates. Any sniff of lacklustre growth (even if it’s still positive) and the company will be punished. I do wonder if the demand for Alkindi simply isn’t that big. I’d like to see some numbers from Eton as they said demand was very high, but until that happens I’ll be taking their claim with a pinch of salt. Still early days and Chronocort approval very much needed or DNL is toast. All commentary on this topic is very positive though so the likelihood of approval seems strong. At least the balance sheet is in good shape.
Nice to see someone who already has a significant stake increase further. Buying the rest or Norwood’s stake perhaps? Generally quite a quiet stock this one.
A 5,969,332 @ 20p chonker reported late. Looking at price movement and other trades around that time, I’m thinking a sale, however, every sale is a buy and vice versa. Wonder if filling that order is what’s held it down today. Either way it’s nice to see some life here.
And an algo smashes the price back down. Hardly appropriate to sell so many 15k blocks like that all within the space of a second. Nice...
4.5m share trade showing up. Would be nice to finally see some interesting news here. Although I do not have a position anymore, the recent price rise and volume has caught my eye again.
It’s interesting to me that a stock of this mcap has the liquidity to absorb a 2m sale without it being a delayed, worked order. It’s always been very easy to buy and sell very sizeable chunks.
Sensibles I think they need someone on board ASAP because they cannot do it alone. It’s a bold quest, but in this case, SOLG just don’t seem to have what it takes.